ABVC
ABVC BioPharma, Inc.2.0600
-0.0070-0.34%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
50.06MP/E (TTM)
-Basic EPS (TTM)
-0.28Dividend Yield
0%Recent Filings
8-K
8-K
ABVC assets double in Q2
ABVC BioPharma reported Q2 2025 results with total assets surging 103% to $16.2 million from $8.0 million a year earlier, fueled by affiliate equity gains and better allocation. Shareholders' equity climbed to $9.5 million, while diluted EPS loss narrowed to $(0.13) from full-year 2024's $(0.42). Post-quarter, the company acquired $3.3 million Taiwan farmland for R&D and GMP expansion, plus $350K July licensing revenue from partners. This bolsters vertical integration but hinges on regulatory approvals.
10-Q
Q2 FY2025 results
ABVC BioPharma posted zero revenue in Q2 FY2025 ended June 30, 2025, down 100% y/y from $117K, while operating expenses climbed 135% y/y to $2.3M on higher stock-based compensation, yielding an operating loss of $2.3M, up 167% y/y. Net loss widened to $2.3M or $0.13 per diluted share from $1.0M or $0.08, with the gap to operating loss tied to $1.6M in stock-based comp and $129K interest expense. Cash dipped to $388K from $248K y/y, but total assets swelled to $16.2M on $7.7M land acquisition in Taiwan via AiBtl shares; working capital deficit narrowed to $3.8M. Financing inflows of $2.4M from private placements and warrant exercises offset $1.4M operating cash burn. Yet Nasdaq compliance hangs by a thread on equity and bid price rules.
8-K
Shareholders approve key proposals
ABVC BioPharma shareholders overwhelmingly re-elected all 11 directors and ratified Simon & Edward, LLP as auditors for 2025 at the June 3 annual meeting, with 35.27% turnout. They greenlit a related-party land purchase from director Shuling Jiang via stock and warrants, potentially diluting shares over 20% and risking Nasdaq change-of-control scrutiny. The equity plan expanded to 15% of outstanding shares, auto-increasing 5% yearly from 2026. Continuity holds, but dilution looms.
8-K
Q1 loss shrinks; Taiwan land eyed
ABVC BioPharma slashed operating expenses 76% to $693,005 in Q1 2025, trimming net loss 68% to $944,190 from Q1 2024's $2.93 million. The company recognized a $7.67 million land asset in Taiwan, eyeing an AI-powered agricultural facility for sustainable botanical sourcing. This vertical integration push bolsters drug pipeline consistency. No assurance the project materializes amid financing risks.
ABP
Abpro Holdings, Inc
4.98-0.79
ABVX
Abivax SA
110.98-6.93
AVBP
ArriVent BioPharma, Inc.
23.11-0.53
BCAB
BioAtla, Inc.
0.76-0.01
BIVI
BioVie Inc.
1.43+0.00
INMB
INmune Bio Inc.
1.89-0.02
NUVB
Nuvation Bio Inc.
8.66+0.15
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
TOVX
Theriva Biologics, Inc.
0.21+0.01
VINC
Vincerx Pharma, Inc.
0.01+0.00